CTI BioPharma Corp (CTIC) : Bvf Incil scooped up 1,001,327 additional shares in CTI BioPharma Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 44,796,940 shares of CTI BioPharma Corp which is valued at $15,589,335.CTI BioPharma Corp makes up approximately 3.50% of Bvf Incil’s portfolio.
Other Hedge Funds, Including , Two Sigma Advisers Lp sold out all of its stake in CTIC during the most recent quarter. The investment firm sold 11,200 shares of CTIC which is valued $3,898.Vanguard Group Inc reduced its stake in CTIC by selling 689,378 shares or 8.28% in the most recent quarter. The Hedge Fund company now holds 7,638,471 shares of CTIC which is valued at $2,658,188. State Board Of Administration Of Florida Retirement System sold out all of its stake in CTIC during the most recent quarter. The investment firm sold 131,920 shares of CTIC which is valued $46,964. Sg Americas Securities sold out all of its stake in CTIC during the most recent quarter. The investment firm sold 157,960 shares of CTIC which is valued $56,866.
CTI BioPharma Corp closed down -0.003 points or -0.76% at $0.39 with 8,38,084 shares getting traded on Thursday. Post opening the session at $0.399, the shares hit an intraday low of $0.39 and an intraday high of $0.4061 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
CTI BioPharma Corp. (CTI) formerly Cell Therapeutics Inc. is a biopharmaceutical company focused on the acquisition development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone) or PIXUVRI in the European Union for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.